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Abstract
Introduction Medication changes involving levothyrox-
ine—either dose titrations or switching formulations—oc-
cur frequently in patients with erratic thyroid-stimulating
hormone (TSH) levels and persistent hypothyroid symp-
toms. We investigated whether switching patients from
levothyroxine tablets to a gel cap formulation of levothy-
roxine might reduce dose adjustments and improve toler-
ability and efficacy outcomes.
Objectives Primary study objectives included quantifying
the percentage of patients achieving TSH levels within a
pre-specified range, median dose changes experienced, and
the percentage of patients with improved hypothyroid
symptom control after switching from levothyroxine
tablets to levothyroxine gel caps.
Methods A retrospective medical chart review was con-
ducted among 99 randomly selected hypothyroid patients
who were switched from a tablet to a gel cap formulation of
levothyroxine. Patients were required to have been on
levothyroxine monotherapy for C1 year prior to the med-
ication switch. Data was collected for 6 months pre-switch
and up to 6 months post-switch.
Results Of the 99 patients studied, the majority (51.5%)
experienced no documented change in TSH status after the
switch (P\ 0.0001). However, there was a decrease in the
mean number of dose changes experienced (1.61 ± 0.96
vs. 0.73 ± 0.96; P\ 0.0001). Improved hypothyroid
symptom control was reported among 61.6% of patients
(61 of 99; P\ 0.0001).
Conclusion The results of CONTROL Switch support a
strategy of switching patients who may experience
tolerability or efficacy problems with standard
levothyroxine tablets to the levothyroxine gel cap
formulation.
Key Points
Changes in levothyroxine doses or formulations are
common and can increase the use of healthcare
resources and lead to poor clinical outcomes.
Levothyroxine gel caps are a unique formulation that
has been proven to be consistently absorbed in the
presence of factors that limit the absorption of
levothyroxine tablets.
When patients were switched from levothyroxine
tablets to gel caps, the majority experienced no
improvement in TSH status but significant reductions
in dose changes and significant improvement in
hypothyroid symptom control.
The results of the study were consistent regardless of
the reason for medication switch (efficacy or adverse
effects) or prior therapy (branded or generic
levothyroxine tablets).
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1 Introduction
1.1 Background on Disease
Hypothyroidism is a common endocrine disorder resulting
from deficiency of thyroid hormone. It is typically a pri-
mary process in which the thyroid gland is unable to pro-
duce sufficient amounts of thyroid hormone [1].
Third-generation thyroid-stimulating hormone (TSH)
assays are readily available and are generally the most
sensitive screening tool for primary hypothyroidism. The
generally accepted reference range for normal serum TSH
is the one contained in the most recent guidelines from the
American Thyroid Association (ATA): 0.40–4.2 mIU/L
[2].
1.2 Treatment
For hypothyroidism, thyroid hormone is administered to
supplement or replace endogenous production—typically
levothyroxine—the ‘gold standard’ of treatment for over
60 years. It is one of the most frequently used medications
in the USA, with over 115 million prescriptions dispensed
in 2013 [3].
In general, hypothyroidism can be adequately treated
with a consistent daily dose of levothyroxine, which is
determined after a period of initial dosing and titration.
However, many patients continue to require dose changes
during the course of therapy due to erratic biochemical
control of hypothyroidism or persistent hypothyroid
symptoms [4–9].
1.3 Levothyroxine Dose Changes
In the recently completed CONTROL Surveillance Project
conducted in 925 patients taking levothyroxine monother-
apy (94% for [2 years), 23.4% of respondents reported
that they had experienced one levothyroxine dose change
in the prior 12 months; 8% reported experiencing two or
more dose changes in the past 12 months [10]. Thus, there
appears to be a subset of patients whose hypothyroidism is
difficult to control (biochemically and/or symptomatically)
with traditional levothyroxine tablet therapy.
The common strategy of escalating the dose of
levothyroxine with adjustments until targeted TSH status is
achieved can increase overall healthcare costs and may
lead to worsened outcomes. In the recently completed
CONTROL HE (Health Economics) study, medical charts
from 454 randomly selected patients were analyzed. Con-
sumption of healthcare resources over a 24-month period
(as measured by direct medical costs and the value of lost
work productivity) was observed to increase significantly
with each successive change in levothyroxine dose or
formulation [11]. Changes to levothyroxine dosing have
also been associated with the risk for prolonged exposure
to supratherapeutic doses of levothyroxine [2, 12–14]. Data
from five different studies have demonstrated that exces-
sive exposure to levothyroxine is common, ranging from
14 to 22% of all patients [15–19]. Over-exposure to
levothyroxine has been associated with adverse cardio-
vascular events and bone loss [12].
1.4 Factors that Necessitate Levothyroxine
Changes: Clinical Implications
Common factors that can necessitate levothyroxine dose
adjustments include lack of medication persistence, changes
in medication dosage, dosage errors, concomitant medical
conditions/medications, switching to less bioavailable generic
products, body mass changes, and diet. Because levothyrox-
ine is a drug with a narrow therapeutic index, and its
absorption is dependent on gastric pH, some co-morbidities
may interfere with its absorption by altering gastric acidity
[20–25].
Medication changes involving levothyroxine—either
dose titrations or switching formulations—are frequent
contributors to poor control of both TSH and hypothyroid
symptoms [26]. In a recent large survey conducted by the
American Association of Clinical Endocrinologists
(AACE), ATA, and the Endocrine Society (ES), the
majority of adverse outcomes associated with the generic
substitution of levothyroxine products resulted in either
mild symptoms of hypo- or hyperthyroidism and/or unex-
pected thyroid function tests that fell outside of normal
limits, almost certainly resulting in lost productivity/wages,
travel for further testing, and associated follow-up care
[27].
1.5 Rationale for Study
Levothyroxine gel caps constitute a unique formulation
that has been shown to produce consistent absorption even
in the presence of factors that inhibit the absorption of
standard tablet formulations of levothyroxine [28–31].
Given that the gel cap is free of many excipients known to
cause tolerability problems (such as gluten), it seemed
plausible that it may also be better tolerated. We hypoth-
esized that switching difficult-to-control hypothyroid
patients from tablet formulations of levothyroxine to the
gel caps might reduce the need for dose adjustments,
improve tolerability, and enhance efficacy outcomes in
hypothyroid patients. In order to prove this, we undertook a
retrospective chart review of patients previously on tablet
formulations of levothyroxine who were switched to the
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gel cap. Such an evaluation had not previously been
conducted.
2 Objectives of CONTROL Switch
The main objectives of our study were to quantify the
percentage of patients who achieve TSH status within the
ATA-recommended reference range of 0.40–4.2 mIU/L
[2], the median number of dose changes experienced, and
the percentage of patients with improved hypothyroid
symptom control after switching from levothyroxine
tablets to levothyroxine gel caps. Other objectives included
describing patient characteristics, including any relevant
co-morbidities, among the study cohort.
3 Methods
A retrospective medical chart review was conducted
among randomly selected patients of providers in
community healthcare practices across the USA. All
patients who met study inclusion criteria had their
medical charts abstracted by trained nurses. Each nurse
abstractor was trained on and pre-certified to use the
Institutional Review Board (IRB) approved data col-
lection instrument. Study design and methods are shown
in Appendix 1.
3.1 Study Populations
The target population consisted of 100 patients who had
been treated with levothyroxine tablets for at least 1 year
and whose medication had been changed from a tablet to
the gel cap formulation. Patients were required to have
been taking levothyroxine gel caps for 3–6 months post
medication switch and to have medical charts that con-
tained sufficient relevant data (see Appendix 2).
Table 1 provides a complete description of inclusion
and exclusion criteria.
3.2 Study Period
Medical chart data were collected and reviewed for docu-
mented information on patients meeting inclusion criteria
for the time period 6 months (minimum) pre-medication
switch through to a period of 3–6 months post treatment
switch.
Patients must have been switched to gel caps no later
than 30 June 2015. Therefore, the chart abstraction range
covered approximately 1 January 2007 (post-US Food and
Drug Administration [FDA] approval of gel caps in late
2006) through to 31 December 2015.
3.3 Data Sources
Electronic Medical Records (EMRs) and paper medical
records from participating research sites were utilized to
identify relevant patients for data collection. Appendices 2
and 3 list the information that was collected, including a
full listing of symptoms evaluated and medication adverse
effects captured.
3.4 Statistical Analysis
3.4.1 Study Endpoints/Outcomes, Analysis Sets
Endpoints for this study included:
• Achievement of target TSH status (defined as being
within the ATA-recommended reference range of 0.40-
4.2 mIU/L);
• Improvement in hypothyroid symptom control (as
documented by the treating clinician);
• Number of dose changes after medication switch to
achieve desired clinical results.
All patients meeting the entry criteria were analyzed in
the full analysis.
3.4.2 Sample Size Considerations
Assuming the mean reduction in the number of dose
changes following the switch to gel caps to be one, and a
standard deviation (SD) of three dose changes, a sample
size of 97 patients would provide 90% power at a = 0.05
(two-sided) to test the hypothesis.
We also estimated that somewhere between 50 and 80%
of patients would achieve their target TSH status and
hypothyroid symptom control with two or fewer dose
changes after being switched to gel caps. A sample size of
100 patients would provide an estimate of this percentage
within a 95% confidence interval of ± 10%.
3.4.3 Planned Analyses
Data outlined in Appendix 2 were extracted to allow six
research questions to be answered through this study
(Appendix 4).
3.4.4 Planned Method of Analysis
Descriptive and univariate analyses were conducted on
abstracted variables before and after switch to gel caps,
with inferential statistics including t tests and Chi-square
tests used when appropriate. Statistical significance was
evaluated at the two-sided 0.05 a level. A complete
explanation of the analysis is available in Appendix 4.
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4 Informed Consent
To ensure the research was in compliance with HIPAA
(Health Insurance Portability and Accountability Act of
1996) legislation, an IRB waiver of authorization was
obtained from Sterling IRB, Atlanta, GA, USA, according
to 45 CFR 164.512 (i)(1)(i), which allowed the collection
of protected health information without the authorization of
study participants for research purposes.
5 Patient Confidentiality
Patients’ confidentiality was maintained for documents
submitted to the study Sponsor. Patients were identified
only by a unique identification number, and, where per-
mitted, date of birth was documented and formatted in
accordance with local laws and regulations.
6 Results
6.1 Demographics
Charts from 99 patients contained the information required
for inclusion. The mean age for the entire cohort was
43.9 years, and 91% of patients were female; 40% were
white, 4% Asian, 2% African American, and 53% did not
specify race; 2% of patients were of Hispanic or Latino
ethnicity. Most patients (75%) were taking branded
levothyroxine tablet formulations pre-switch (Table 2). All
patients were under the care of an endocrinologist.
Consistent with prior studies, there was a high preva-
lence of patients with co-morbid conditions that are known
to complicate levothyroxine therapy. A total of 34.3%
patients (34/99) had at least one reported co-morbidity. The
majority (65.7%; 65/99) had no reported co-morbid con-
dition. The following conditions were noted most fre-
quently in medical records: gastroesophageal reflux disease
Table 1 Inclusion/exclusion criteria
Inclusion criteria
Age C18 years old and taking levothyroxine tablet monotherapy to treat the symptoms of hypothyroidism
On levothyroxine for 1 year or longer
Having experienced C1 changes in levothyroxine tablet dose or formulation in the 6 months prior to being switched to levothyroxine gel
caps
Currently taking levothyroxine gel caps for at least 3 months
Documentation of the lack of TSH and hypothyroid symptom control for at least 1 visit within 6 months prior to medication switch
Documentation of at least 1 physician visit after medication switch including TSH values and notes regarding hypothyroid symptom control
Exclusion criteria
Patients were excluded from the study if any of the following criteria were met
Absence of inclusion criteria
Patient was pregnant at any time during the study period
Patients taking T3 therapy (i.e., Cytomel or generic T3 therapy), T3/T4 combination therapy (i.e., Armour Thyroid) or the Levoxyl
brand of T4 tablets
Patients suspected by treating clinician of poor compliance with levothyroxine therapy
TSH thyroid-stimulating hormone
Table 2 Summary of demographics (n = 99 total patients in
levothyroxine gel caps switch cohort)
Demographic n (%)a
Mean age ± standard deviation (years) 43.9 ± 11.8












Not Hispanic/Latino 10 (10)
Unknown 87 (88)
Pre-switch therapy
Branded levothyroxine tablets 74 (75)
Generic levothyroxine tablets 25 (25)
a Unless otherwise specified
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(GERD) (11.1%), thyroid cancer (10.1%), celiac disease
(6.1%), gastric bypass (3%), and irritable bowel syndrome
(IBS) (3.0%) (see Table 3). Concomitant medications/di-
etary supplements that were noted in medical records for
the entire cohort (n = 99) included calcium (15% of
mentions), iron (17% of mentions), histamine H2 receptor
antagonists (9% of mentions), and proton pump inhibitors
(PPIs) (6% of mentions).
6.2 Reasons for Medication Changes
Among patients with documented reasons for switching to
gel caps (n = 82), the most common reason for switching
was adverse effects associated with prior therapy (n = 49,
59.8%). Reasons cited in medical chart notes include gas-
trointestinal-related adverse effects such as cramps and
bloating and miscellaneous other adverse effects including
insomnia, urticaria, and hair loss. Ineffectiveness of the
previous medication was the next most common reason for
switching to gel caps, documented in 39 (47.6%) patient
records. In these cases, inadequate biochemical (TSH) and
hypothyroid symptom control were the most cited. It
should be noted that some patients were switched to gel
caps for both reasons—adverse effects and suboptimal
efficacy (n = 14).
6.3 Thyroid-Stimulating Hormone (TSH) Status
Among the full cohort of 99 patients switched to gel caps,
51.5% had no documented change in TSH status compared
with prior to switch (P\ 0.0001) (Fig. 1). More than 26%
of patients had a documented improvement in their TSH
status (26/99). Only a minority of patients (22.2%) expe-
rienced a worsening of their TSH status post-switch.
6.4 Dose Adjustments
Among the full cohort of 99 patients, 85.8% experienced
one or fewer dose changes post-switch (33.3% experienced
one dose change; 52.5% did not experience any dose
changes). Prior to switching to gel caps, the study cohort
experienced a mean of 1.61 ± 0.96 dose adjustments per
patient; after switching to gel caps, the study cohort
experienced a mean of 0.73 ± 0.96 dose adjustments per
patient, a statistically significant change (P\ 0.0001)
(Fig. 2). The post-switch mean of 0.73 ± 0.96 dose
adjustments per patient is a 54.7% decrease from the pre-
switch mean number of dose adjustments.
6.5 Symptom Control
Among the full cohort of 99 patients, 61.6% had physician-
reported improvement of symptoms following switch to the
gel caps formulation (P\ 0.0001). Only 8.1% reported
worsening of symptoms post-switch (Fig. 3).
Table 3 Percentage of patients with co-morbid conditions (n = 34
with at least one co-morbid condition; 34.3% of entire cohort)
Co-morbid conditiona n (%)
No co-morbid condition 65 (65.7)
GERD 11 (11.1)
Thyroid cancer 10 (10.1)
Celiac disease 6 (6.1)




Helicobacter pylori 1 (1.0)
Lactose intolerance 1 (1.0)
Ulcerative colitis 1 (1.0)
GERD gastroesophageal reflux disease, IBS irritable bowel syndrome
a Patients may have had more than one co-morbidity documented in
the medical record
0 10 20 30 40 50 60
Improving                26 (26.3)
No change                                                              51 (51.5)*
Worsening                                             22 (22.2)
Number (%) of Patients in TSH Status Category
N = 99 Total Patients in Levothyroxine Gel Caps Switch Cohort
*P < 0.0001, Chi square goodness-of-fit test
Fig. 1 Thyroid-stimulating hormone status (in range or out of range)
post-switch [n (%) of patients]. TSH thyroid-stimulating hormone
0.0 0.5 1.0 1.5 2.0
Pre-Switch
to Levothyroxine                                   1.61 (± 0.96)
Gel Caps
Post-Switch
to Levothyroxine                 0.73 (± 0.96)*
Gel Caps
Mean Number of Dose Adjustments Per Patient (Standard Deviation)
N = 99 Total Patients in Levothyroxine Gel Caps Switch Cohort
*P < 0.0001, 2-sided paired t-test
Fig. 2 Dose adjustments pre- and post-switch
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6.6 Patients Switched for Efficacy Reasons Only
6.6.1 TSH Status
Among patients who were switched for efficacy reasons,
almost one-third (32%; 8/25) experienced an improvement
in TSH status post-switch. Most experienced no change
(48%; 12/25). Only a minority of patients (5/25) experi-
enced a worsening of TSH status after the switch. How-
ever, this result was not statistically significant
(P = 0.2276).
6.6.2 Dose Adjustments
Among those patients who were switched for efficacy
reasons, 88% (22/25) had one or fewer dose changes after
switching to the gel cap (20% had one dose change; 68%
experienced no dose adjustments). Prior to switching to gel
caps, these patients experienced a mean of 1.60 ± 0.92
dose adjustments per patient. After switching to gel caps,
this cohort experienced a mean of 0.44 ± 0.71 dose
adjustments per patient, a statistically significant change of
72.5% from the pre-switch mean number of dose adjust-
ments (P\ 0.0001) (Fig. 4).
6.6.3 Symptom Control
Among patients switched for efficacy reasons, 64% (16/25)
had physician-reported improvement in hypothyroid
symptoms. Among those with no documented improve-
ment in hypothyroid symptoms, the majority (7/9) experi-
enced no change in symptoms. Only two patients (8%)
experienced a worsening of their hypothyroid symptoms
(Fig. 5).
7 Discussion
The results of CONTROL Switch showed improvements
across a wide range of clinical variables when hypothyroid
patients were switched from standard levothyroxine tablet
formulations to levothyroxine gel caps. However, these
results should be viewed within the context of the
following:
• The patient population studied;
• Differences in results among patients switched for
efficacy reasons versus non-efficacy reasons;
• Changes in symptom control versus changes in TSH
status;
• Data collection period pre-/post-switch; and
• Similarity or discordance with prior clinical studies.
7.1 Patient Population
The patient population in CONTROL Switch differed from
those of prior studies. These differences include:
• Patient age Patients in CONTROL Switch were
younger (average age was 43.9 years). Current
AACE/ATA guidelines list the prevalence of hypothy-
roidism among adult women in the USA to be as high
0 10 20 30 40 50 60 70 80
Improving             61 (61.6)*
No change         30 (30.3)
Worsening               8 (8.1)
Number (%) of Patients in Symptom Control Category with
Physician Documented/Patient-Reported Documentation
of Symptom Control
N = 99 Total Patients in Levothyroxine Gel Caps Switch Cohort
*P < 0.0001, Chi square goodness-of-fit test
Fig. 3 Symptom control post-switch [n (%) of patients]
0.0 0.5 1.0 1.5 2.0
Pre-Switch
to Levothyroxine           1.60 (± 0.92)
Gel Caps
Post-Switch
to Levothyroxine                           0.44 (± 0.71)*
Gel Caps
Mean Number of Dose Adjustments Per Patient (Standard Deviation)
n = 25 Patients Switched to Levothyroxine Gel Caps
Due to Lack of Efficacy Only
*P < 0.0001, 2-sided paired t-test
Fig. 4 Dose adjustments pre- and post-switch (efficacy reasons only)
0 5 10 15 20
Improving                                                         16 (64)*
No change        7 (28)
Worsening              2 (8)
Number (%) of Patients in Symptom Control Category with
Physician Documented/Patient-Reported Documentation
of Symptom Control
n = 25 Patients Switched to Levothyroxine Gel Caps
Due to Lack of Efficacy Only
*P = 0.0024, Chi square goodness-of-fit test
Fig. 5 Symptom control post-switch [n (%) of patients]
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as 12 per 1000 [2, 32]; the average age of patients is
estimated at 58 years [2].
• Co-morbidities The number of patients with gastroin-
testinal conditions (25.3%) is lower than that observed
in other studies. In CONTROL Surveillance, a survey
of 925 patients taking levothyroxine monotherapy,
47.0% of patients reported having one or more
gastrointestinal condition that could affect levothyrox-
ine therapy. Among these conditions, GERD (33.8%)
and IBS (9.7%) were most prevalent [10].
• Thyroid cancer surgery The prevalence of patients in
the study who had experienced thyroid cancer surgery
(10.1%) is also higher than that observed in the general
population and may have influenced treatment deci-
sions, especially the range of TSH values to which
patients were managed.
• Gastrointestinal surgery The percentage of patients
with a history of gastric surgery in CONTROL Switch
(3.0%) was higher than that observed in prior studies.
Gastric surgery has been shown to limit the absorption
of oral drug therapy, including levothyroxine [33].
Prior therapy Given the widely documented issues of
consistency and potency noted among generic formulations
of levothyroxine [27], it is reasonable to expect that
patients taking generic levothyroxine formulations would
see different results than patients taking branded levothy-
roxine formulations when switched to the gel cap. In
CONTROL Switch, reductions in dose changes post-switch
were similar among both groups. Prior to switching to gel
caps, patients on branded levothyroxine tablets experienced
a mean of 1.62 ± 0.72 dose adjustments per patient. After
switching to gel caps, this cohort experienced a mean of
0.72 ± 0.93 dose adjustments per patient. The relative
decrease of 55.6% in mean dose adjustments pre- and post-
switch is comparable with that in patients switched from
generic levothyroxine tablets (55.6 vs. 51.3%). There was
no statistically significant difference in the mean number of
dose adjustments between patients switched to gel caps
from branded levothyroxine tablets and those switched
from generic tablets (P = 0.8541) (Fig. 6). Both groups
experienced similar improvements in hypothyroid symp-
tom status: almost 61% (45/74) of patients on branded
levothyroxine tablets pre-switch had documented physi-
cian- or patient-reported improvement of symptoms fol-
lowing the switch to gel caps, compared with 64.0% (16/
25) of patients on generic levothyroxine tablets pre-switch.
The result was not statistically significant, indicating there
was no statistical difference in physician- or patient-re-
ported documentation of symptom control between patients
switched to gel caps from branded levothyroxine tablets
and those switched from generic tablets (P = 0.9562)
(Fig. 7).
Considering these points, it is not unreasonable to con-
clude that the patient population in CONTROL Switch was
somewhat more difficult to manage than the general
hypothyroid population. These make the improvements in
TSH status and hypothyroid symptoms observed in the
study more significant.
7.2 Results: Patients Switched for Efficacy Versus
Adverse Effects
In CONTROL Switch, ‘‘side effects of prior medication’’
was listed as the primary reason for switching medication
for most patients (59.8%). Assuming that many of these
patients had TSH values within the recommended refer-
ence range pre-switch, one would expect little overall
change in TSH status when switching to an alternate
levothyroxine formulation. Results from our study bear this
out. More than 78% of patients switched for ‘‘side effects’’
experienced no change in TSH status post-switch or an
improvement in TSH status. Among patients switched
primarily because of the ‘‘lack of efficacy of prior medi-
cation’’ (n = 25), the percentage of patients whose TSH
status remained in range or improved was 72% (18/25).
Only 28% of these patients (7/25) experienced a worsening
of their TSH status. These results confirm our initial
hypothesis that the clinician’s reason for the medication
switch (lack of efficacy vs. adverse effects) would correlate
to the results observed.
7.3 Changes in Symptom Control Versus Changes
in TSH
In CONTROL Switch, the records of most patients indicate
a notable improvement in hypothyroid symptom control
post-medication switch. Patients switched for efficacy
reasons experienced a greater improvement in hypothyroid
symptom control (64.0%) than those switched primarily for
non-efficacy reasons (62.8%; P[ 0.05). The improvement
in hypothyroid symptom control observed among patients
switched for non-efficacy reasons may be attributable to
improvements in medication tolerability. Briesacher et al.
[34] and Kandukuri et al. [35] have demonstrated a strong
correlation between drug tolerability or adverse effects and
medication compliance.
Improvements in hypothyroid symptom control were
observed even in the absence of laboratory test values that
were within the recommended reference range. Among
patients who experienced a worsening of their TSH status
post-switch, 45.5% (10/22) experienced an improvement
in hypothyroid symptom control post-switch. While
seemingly paradoxical, this illustrates a phenomenon
found frequently in clinical practice: the divergence
between TSH values and patient symptoms. While the
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possibility of a ‘placebo effect’ cannot be ruled out,
Hulisz [36] observed that some patients experience a
‘‘lack of well-being’’ in spite of reaching the euthyroid
reference range of TSH. We view these data as hypothesis
generating and advocate further study in a prospective and
controlled trial.
7.4 Data Collection Period
In CONTROL Switch, there was a difference in the data
collection period pre- and post-medication switch which
could bias study results. Per protocol, data were collected
for 6 months pre-switch and 3–6 months post–switch.
When study results were examined, it was determined that
almost 86% of study subjects (85/99) had their data ana-
lyzed for 6 months or more post-switch. Among these
patients, there was no statistical difference in the number of
dose changes experienced versus the entire study cohort
(0.788 ± 0.989 vs. 0.727 ± 0.956; P[ 0.05). Among
patients whose records contained data for between 3 and
6 months post-switch (n = 14), there was also no statisti-
cal difference in the number of dose changes experienced
versus the entire study cohort (0.429 ± 0.64 vs.
0.727 ± 0.956; P[ 0.05). These data further support the
robustness of the results observed in the study.
7.5 Similarity with Prior Studies
The results of CONTROL Switch are congruent with, and
extend the results of, other studies involving levothyroxine
gel caps. In a 2015 study, Santaguida et al. [31] reported
that patients switched from tablet formulations of
levothyroxine were able to be managed at a lower dose of
levothyroxine gel caps. In CONTROL Switch most
patients experienced no change in dose after initiation on
the gel cap formulation. Among patients switched for
efficacy reasons, a group among whom dose adjustments
may be more likely, the majority who experienced dose
changes post-switch had their medication titrated down-
ward (62.5%; 5/8) rather than upward (37.5%; 3/8).
CONTROL Switch further documents the utility of the
gel cap formulation in treating patients with gastrointesti-
nal disorders or other factors that may contribute to sub-
optimal and/or variable levothyroxine absorption. Among
patients with gastrointestinal disorders in the study, there
was a 36.3% reduction in the mean number of dose changes
0.0 0.5 1.0 1.5 2.0
Pre-Switch
to Levothyroxine             1.62 (± 0.72)
Gel Caps
Post-Switch
to Levothyroxine                                           0.72 (± 0.93)*
Gel Caps
Mean Number of Dose Adjustments Per Patient (Standard Deviation)
n = 74 Patients Switched to Levothyroxine Gel Caps
from Branded Levothyroxine Tablets
*P = NS, t-test
0.0 0.5 1.0 1.5 2.0
Pre-Switch
to Levothyroxine          1.56 (± 1.47)
Gel Caps
Post-Switch
to Levothyroxine                                             0.76 (± 1.05)*
Gel Caps
Mean Number of Dose Adjustments Per Patient (Standard Deviation)
n = 25 Patients Switched to Levothyroxine Gel Caps
from Generic  Levothyroxine Tablets
*P = NS, t-test
Fig. 6 Dose adjustments pre- and post-switch from branded (left) or generic (right) levothyroxine to gel caps. NS not significant
0 20 40 60 80
Improving                                                    60.8*
No change           31.1
Worsening               8 .1
Percentage of Patients in Symptom Control Category with
Physician Documented/Patient-Reported Documentation
of Symptom Control
n = 74 Patients Switched to Levothyroxine Gel Caps
from Branded  Levothyroxine Tablets
*P = NS, Chi square Test of Independence
0 20 40 60 80
Improving                                                         64.0*
No change      28.0
Worsening               8 .0
Percentage of Patients in Symptom Control Category with
Physician Documented/Patient-Reported Documentation
of Symptom Control
n = 25 Patients Switched to Levothyroxine Gel Caps
from Generic Levothyroxine Tablets
*P = NS, Chi square Test of Independence
Fig. 7 Symptom control post-switch from branded (left) or generic (right) levothyroxine to gel caps. NS not significant
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(1.83 ± 0.41 pre-switch reduced to 1.17 ± 1.83 post-
switch). Improvements in hypothyroid symptom control
were also observed. Among patients with gastrointestinal
conditions (n = 25), 68% experienced an improvement in
hypothyroid symptoms post-switch. The remainder (32%;
8/25) experienced no change. These results may be
explained in part by the fact that the gel cap formulation is
more fully absorbed when gastric pH is affected by certain
gastrointestinal conditions, medications, or dietary sup-
plements [28–31, 37]. In the case of patients with GERD,
improved hypothyroid symptom control may be the result
of the pharmacokinetics of the gel cap versus standard
tablet formulations in the presence of PPIs. Seng Yue et al.
[28] demonstrated the superior absorption of levothyroxine
gel caps in individuals with altered gastric pH resulting
from the coadministration of esomeprazole.
Given its lack of sensitizing excipients, it is not sur-
prising that many patients were switched to the gel cap
formulation after experiencing ‘‘side effects’’ with tradi-
tional levothyroxine therapies. McMillan et al. [10]
reported that medical conditions that can be exacerbated by
excipients found in tablet therapies may be present in as
many as 15% of all levothyroxine-treated patients. In
CONTROL Switch, 7.1% of patients had documentation in
their medical charts indicating the presence of either celiac
disease or lactose intolerance. However, these conditions
are often undiagnosed. These patients experienced com-
parable reductions in dose changes relative to the overall
study population. A majority of patients with celiac disease
(83.3%; 5/6) experienced improvements in symptom con-
trol. The effect of the gel cap formulation in reducing dose
changes and improving hypothyroid symptom control
among patients with known medication tolerability con-
cerns is further proof of its utility in treating these patients.
8 Study Limitations
Though adequately powered, our study involving 99
patients may not fully represent the broader hypothyroid
patient population. There were a number of demographic
differences found in this cohort of patients compared with
the population at large, as reported in the medical litera-
ture. For example, a smaller percentage of African Amer-
icans (2%) was observed in our study than in the broader
hypothyroid population (14%). The reason for this dis-
crepancy is unclear.
Data were extracted if documented within patient charts.
Certain datapoints, including demographic and co-mor-
bidity information, were missing if they were not present in
medical records. Missing data values were not assigned
(imputed) based on inference from other known values.
For the analyses on dose changes, symptom control, and
TSH status, there was no adjustment made to account for
patient age, pregnancy status, etiology of hypothyroidism,
or co-morbid conditions such as thyroid cancer. These
factors are known to affect response to levothyroxine
therapy and influence physician decisions regarding
levothyroxine dosing [2, 38–42]. The symptom control
analysis may have been improved by using a more detailed
data collection instrument.
Finally, this was a retrospective study, not randomized,
blinded, or placebo controlled. It should be noted that
retrospective data analyses, by design, cannot establish
cause and effect. Only a randomized, prospective study can
draw such definitive conclusions.
9 Conclusions
Levothyroxine dose and medication changes are common
in clinical practice and often result from lack of tolerability
or intended efficacy. They may also contribute to unnec-
essary utilization of healthcare resources and patient dis-
satisfaction with care [26]. Minimizing levothyroxine dose
and formulation changes may therefore be an appropriate
strategy to both optimize healthcare resources and improve
patient satisfaction. Our study suggests that for some
patients, a strategy of switching from traditional levothy-
roxine tablet therapy to levothyroxine gel caps may elim-
inate or lower the need for such changes while improving
hypothyroid symptom control.
The results of the CONTROL Switch study add to the
growing body of evidence demonstrating the potential
challenges of managing hypothyroid patients with
levothyroxine. Suboptimally treated hypothyroidism,
manifested by frequent levothyroxine medication or dose
changes and/or poor symptom control, can produce unde-
sirable clinical and societal outcomes. The utility of a
strategy of switching from traditional levothyroxine tablet
therapy to levothyroxine gel caps may offer an alternative
that holds the possibility of improved quality of life for
many patients.
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Appendix 1
See Fig. 8.
Study Manager submitted final approved protocol to Sterling IRB and obtained
protocol approval and HIPAA waiver of authorizations for medical record reviews. 
Study Manager recruited study sites by sending a letter to a target list of
primary care providers (PCPs) or endocrinologists in the United States who were deemed
to be high prescribers of the levothyroxine gel cap formulation. 
After a site identified medical records that qualified for the study, providers sent a random sample
of 10 medical records to Study Manager for review.
Medical Chart review conducted and data abstracted by trained clinicians.
Data managed and prepared for final reporting.
Fig. 8 Study design schema.
HIPAA Health Insurance
Portability and Accountability
Act of 1996, IRB Institutional
Review Board
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IBS (irritable bowel disease)
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Labsa TSH labs over 6 months pre- and
6 months post-switch
TSH/serum thyrotropin
Medications/diet (dose, start date,









TSH at time of medication
change or dose adjustment





Levothyroxine gel capsinitiation Adverse effects of levothyroxine
medications, where identified
Documented use or prescription
of proton pump inhibitors
(prescription or OTC),
histamine H2 receptor
antagonists, calcium or iron
supplements, soy products,
chromium picolinate, high-fiber
diet, or foods rich in iron (i.e.,
sushi)




























BMI body mass index, OTC over-the-counter, TSH thyroid-stimulat-
ing hormone
a Includes levels/results, test dates, and any mention of control (or
within/beyond normal limits)
b Note any mention of symptoms as ‘control/controlled’
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Appendix 4
See Table 6.
Planned Method of Analysis
Both descriptive and univariate analyses were conducted to
compare abstracted variables for each patient before and
after switch to gel caps. Two-sided P values \0.05
denoting statistical significance were reported where
applicable, and continuous variables were presented as data
that included n, mean, standard deviation, median,
interquartile range, minimum, and maximum. For
categorical variables, presentation of data included fre-
quency and percentages within each group.
Where applicable for each of the above, inferential
statistics included t tests for important continuous variables
(e.g., age) and Chi square tests for important categorical
variables (e.g., sex, co-morbidities, and others as appro-
priate). Incidence rates for symptoms and control, calcu-
lated on the sample of patients included in the study, were
provided with 95% confidence intervals, and cumulative
incidences were analyzed as well (with confidence limits).
Data were managed in Microsoft Excel and all analyses
were performed in SAS version 9.2 or greater statistical
software (SAS Institute, Cary, NC, USA).
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